In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

A Dutch Biotech Start-Up Launches Its Bid For Clinical Leadership In The Contested Field Of Inherited Retinal Disease

Executive Summary

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

You may also be interested in...



The Medicines Patent Pool Plots A Post-Pandemic Future: Interview With Director Charles Gore

As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.

Pacifying A Pandemic With Numbers

Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health:  can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.

The New Insider Game In Latin America Biotech

Venture capital funds in Latin America have overlooked biotech, leaving an untapped opportunity for local capital markets and US and European investors alike. Chilean entrepreneur Cristian Hernandez, founder of newly launched boutique VC Zentynel Frontier Investments, explains how business – and society – can benefit from launching biotech start-ups able to serve a global market at lower cost.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel